Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases
Funds will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases.
Ray Therapeutics to Present at Upcoming Scientific Conferences
We’re delighted to present our data which shows the power of visual optogenetics as a disruptive technology with the potential to restore vision to many patients with retinal blindness.